Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teneligliptin-Glimepiride DDI Study
NCT03009513Phase 1Completed
- Sponsor
- Handok
- Start
- Jan 2017
- Primary completion
- May 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of teneligliptin in type 2 diabetes mellitus (T2DM), sponsored by Handok. Primary endpoints: Peak Plasma Concentration and Area under the plasma concentration versus time curve. Started Jan 2017; status: completed.
02
Drugs
teneligliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03009513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009513.